| Patrick, Ericka |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B |
|
|
| Completed | 3 | 640 | US, RoW | HEPLISAV-B, ENGERIX-B | National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation | HIV Infection, Hepatitis B | 08/24 | 08/24 | | |
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE |
|
|
| Active, not recruiting | 3 | 310 | US | Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 11/24 | 08/26 | | |
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection |
|
|
| Completed | 2 | 45 | US, RoW | Glecaprevir/Pibrentasvir (G/P), Mavyret | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis C Infection, HIV Infection | 05/23 | 08/23 | | |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
NCT05551273: Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV |
|
|
| Recruiting | 2 | 48 | US, RoW | Selgantolimod, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis B, HIV Infections | 11/26 | 05/27 | | |
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission |
|
|
| Recruiting | 2 | 48 | US, RoW | VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy | National Institute of Allergy and Infectious Diseases (NIAID) | Acute HIV Infection | 04/28 | 09/28 | | |
| Recruiting | 2 | 90 | US, RoW | Estradiol | National Institute of Allergy and Infectious Diseases (NIAID) | HIV I Infection | 05/27 | 05/27 | | |
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 |
|
|
| Recruiting | 1/2 | 45 | US, RoW | ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, GS-2872, 10-1074-LS, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences | HIV-1-infection | 04/26 | 04/26 | | |
NCT05471076: Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV |
|
|
| Active, not recruiting | 1 | 52 | US | 426c.Mod.Core-C4b 30 mcg, Lower dose, 426c.Mod.Core-C4b 100 mcg, Medium dose, 426c.Mod.Core-C4b 300 mcg, Higher dose, Placebo, BG505 | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services | HIV-1-infection | 07/24 | 07/25 | | |
NCT06267872: A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum |
|
|
| Not yet recruiting | 1 | 42 | US, RoW | CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702), Aluminum Hydroxide Suspension (Alum), Alhydrogel, ACU-026-001-1 (labeled as empty LNP) | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, Duke University, Access to Advanced Health Institute (AAHI) | HIV | 12/25 | 09/26 | | |
NCT04177355: Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults |
|
|
| Completed | 1 | 127 | US | BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571 | National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network, International AIDS Vaccine Initiative, Access to Advanced Health Institute (AAHI), Dynavax Technologies Corporation, Fred Hutchinson Cancer Center | HIV Infections | 11/24 | 11/24 | | |
NCT06796686: Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health |
|
|
| Not yet recruiting | 1 | 42 | US | 426c.Mod.Core-C4b, HxB2.WT.Core-C4b, 3M-052-AF adjuvant, Aluminum hydroxide suspension (Alum) adjuvant, Diluent | National Institute of Allergy and Infectious Diseases (NIAID) | HIV | 01/27 | 01/27 | | |
NCT06680479: Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy |
|
|
| Not yet recruiting | 1 | 30 | US | CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection | National Institute of Allergy and Infectious Diseases (NIAID), Duke University, Access to Advanced Health Institute (AAHI) | HIV-1 | 10/26 | 08/27 | | |
NCT05903339: Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV |
|
|
| Active, not recruiting | 1 | 36 | US | V3G CH848 Pr-NP1 60mcg, 3M-052-AF 5mcg, Alum 500 mcg, V3G CH848 mRNA-Tr2 50mcg, ACU-026-001-1 2.0mg, V3G CH848 Pr-NP1 100mcg | National Institute of Allergy and Infectious Diseases (NIAID) | Hiv | 08/25 | 08/25 | | |
NCT00031408: Consent for Use of Stored Patient Specimens for Future Testing |
|
|
| Recruiting | N/A | 30000 | US | | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 12/27 | 12/27 | | |
